Fibroblast Growth Factor Based Therapies for Metabolic Dysfunction

Abstract

Fibroblast growth factor (FGF) based therapies have emerged as a promising area of research and clinical application for the management of metabolic dysfunction, including conditions such as type 2 diabetes mellitus, obesity, and non-alcoholic fatty liver disease (NAFLD). Recent advances in understanding the roles of FGF family members, particularly FGF19 and FGF21, have elucidated their mechanisms in regulating glucose and lipid metabolism, energy expenditure, and insulin sensitivity. This review synthesizes the current evidence regarding the pathophysiological basis of metabolic dysfunction, the clinical potential of FGF-based therapeutics, and their integration into current and emerging treatment paradigms.

Introduction

Metabolic dysfunction encompasses a spectrum of disorders characterized by insulin resistance, dyslipidemia, obesity, and abnormal glucose homeostasis. The rising global prevalence of these conditions underscores the urgent need for novel therapeutic strategies. Fibroblast growth factors, a family of polypeptides with diverse endocrine, paracrine, and autocrine activities, have garnered significant attention due to their regulatory roles in metabolic homeostasis. In particular, the endocrine FGFs—FGF19, FGF21, and FGF23—have shown potential in modulating metabolic processes, offering a mechanistic and translational basis for new therapies.

Epidemiology / Disease Burden

Metabolic dysfunction, principally manifesting as obesity, type 2 diabetes, and NAFLD, represents a major public health crisis. According to the International Diabetes Federation, over 537 million adults were living with diabetes in 2021, with projections indicating a continued upward trend. NAFLD affects approximately 25% of the global population, closely paralleling the obesity epidemic. The burden of these disorders is compounded by their association with cardiovascular disease, chronic kidney disease, and increased mortality, necessitating the development of effective, targeted interventions.

Pathophysiology

The pathophysiology of metabolic dysfunction is multifactorial, involving complex interactions between genetic predisposition, environmental factors, and dysregulation of hormonal and metabolic signaling pathways. Central to these processes is impaired insulin signaling, aberrant lipid metabolism, and chronic low-grade inflammation. FGFs, particularly FGF19 and FGF21, play critical roles in the regulation of bile acid synthesis, gluconeogenesis, lipolysis, and thermogenesis. FGF19 acts primarily on the liver, suppressing bile acid synthesis and promoting glycogen storage, while FGF21 mediates its metabolic effects through adipose tissue and the central nervous system, enhancing insulin sensitivity and energy expenditure.

Risk Factors

Key risk factors for metabolic dysfunction include genetic susceptibility, sedentary lifestyle, high-calorie diets, and coexisting conditions such as polycystic ovary syndrome and sleep apnea. Certain medications, advancing age, and ethnic background further contribute to risk. Recent research suggests that alterations in FGF signaling pathways may not only be a consequence but also a contributor to metabolic derangements, highlighting the importance of targeted interventions.

Clinical Features

Patients with metabolic dysfunction present with a constellation of clinical features ranging from central obesity, acanthosis nigricans, and hypertension to dyslipidemia and impaired glucose tolerance. NAFLD and non-alcoholic steatohepatitis (NASH) may progress silently, while overt diabetes is characterized by hyperglycemia, polyuria, polydipsia, and fatigue. The clinical heterogeneity underscores the need for individualized approaches to diagnosis and management.

Diagnosis

Diagnosis of metabolic dysfunction relies on a combination of clinical assessment, laboratory evaluation, and imaging studies. Key diagnostic criteria include elevated fasting plasma glucose, impaired glucose tolerance, increased waist circumference, hypertriglyceridemia, and reduced HDL cholesterol. Liver imaging and biopsy may be warranted in suspected NAFLD/NASH. Measurement of serum FGF levels is an emerging area of interest, with potential utility in risk stratification and therapeutic monitoring.

Treatment & Management

Management of metabolic dysfunction is multifaceted, focusing on lifestyle modification, pharmacotherapy, and in selected cases, bariatric surgery. First-line interventions include dietary changes, increased physical activity, and weight reduction. Pharmacologic options comprise metformin, GLP-1 receptor agonists, SGLT2 inhibitors, and thiazolidinediones. However, the limitations of existing therapies—particularly in patients with advanced disease or poor response—have propelled the search for novel agents targeting underlying pathophysiology, such as FGF-based therapeutics.

Recent Advances / Emerging Therapies

FGF-based therapies have shown promising results in clinical and preclinical studies. Analogues of FGF19 and FGF21 are being investigated for their ability to improve insulin sensitivity, promote weight loss, and reduce hepatic steatosis. Pegbelfermin (BMS-986036), an FGF21 analogue, has demonstrated significant reductions in liver fat content and favorable effects on lipid profiles in patients with NASH. Aldafermin (NGM282), an engineered FGF19 analogue, has been associated with improvements in liver histology and metabolic parameters. These agents act via specific FGF receptors and co-receptors such as β-Klotho, enabling tissue-selective activity and minimizing off-target effects. Ongoing clinical trials are assessing their long-term safety, efficacy, and potential for integration into standard care.

Guideline Recommendations

While FGF-based therapies are not yet incorporated into major guidelines for metabolic dysfunction, there is growing recognition of their potential. Current recommendations continue to emphasize lifestyle interventions and evidence-based pharmacotherapy. However, expert consensus supports the inclusion of FGF analogues in clinical trials and suggests that, pending robust Phase III data, these agents may soon be considered for patients with refractory or advanced metabolic disease, particularly NAFLD/NASH.

Conclusion

FGF-based therapies represent a significant advance in the management of metabolic dysfunction, offering mechanistic and clinical promise in modulating key metabolic pathways. While further research is needed to establish their long-term efficacy and safety, current evidence supports their potential role as adjuncts or alternatives to existing therapies. Integration of FGF analogues into clinical practice may ultimately improve outcomes for patients with complex metabolic disorders, addressing an urgent and growing healthcare need.